Skip Navigation

JNCI Journal of the National Cancer Institute 1995 87(18):1383-1393; doi:10.1093/jnci/87.18.1383
© 1995 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Erratum (v87,p1807)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gonzalez-Zulueta, M.
Right arrow Articles by Jones, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez-Zulueta, M.
Right arrow Articles by Jones, P. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 87, No. 18, 1383-1393, September 20, 1995
© 1995 Oxford University Press

High Frequency of Chromosome 9p Allelic Loss and CDKN2 Tumor Suppressor Gene Alterations in Squamous Cell Carcinoma of the Bladder

Mirella Gonzalez-Zulueta, Atsuko Shibata, Petra F. Ohneseit, Charles H. Spruck, III, Christer Busch, Mustafa Shamaa, Mustafa Elbaz, Peter W. Nichols, Mark L. Gonzalgo, Per-Uno Malmström, Peter A. Jones*

Urologic Research Laboratory, USC/Norris Comprehensive Cancer Center, University of Southern California Los Angeles
Department of Radiotherapy, Section of Radiobiology, University of Tü, bingenFederal Republic of Germany Sweden
Department of Pathology Sweden
Department of Urology, Uppsala University Sweden
Department of Urology and Nephrology Center Mansoura, Egypt

Correspondence to: Peter A. Jones, Ph.D., USC/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, 1441 Eastlake Ave., Los Angeles, CA 90033-0800.

Background: In the Western Hemisphere, 90% of bladder cancers are transitional cell carcinomas, while only 7% are classified as squamous cell carcinomas. In contrast, in Egypt and regions of the Middle East and Africa, where infection by the trematode Schistosoma haematobium is endemic, squamous cell carcinoma is the most common bladder cancer as well as the most common cancer in men. Purpose: We planned experiments to understand the genetic defects underlying the development of squamous cell carcinoma and to determine if the morphologically and clinically distinct squamous cell carcinoma and transitional cell carcinoma of the bladder evolve following different genetic alterations. Methods: Squamous cell carcinoma specimens from high-risk (Egypt, n = 19) and low-risk (Sweden, n = 12) populations were examined for genetic defects known to be involved in transitional cell carcinoma tumorigenesis. Homozygous deletions of the CDKN2 tumor suppressor gene were detected by comparative multiplex polymerase chain reaction. Mutations in the CDKN2 and p53 (also known as TP53) genes were analyzed by single-strand conformation polymorphism and DNA sequencing. Immunohistochemical staining of p53 protein was also performed. Allelic losses in chromosome arms 9p, 9q, and 17p were determined by microsatellite analysis. Results: Homozygous deletions and sequence mutations in the CDKN2 gene were found in 67% (eight of 12) of squamous cell carcinoma specimens, a frequency three times higher than that reported for uncultured transitional cell carcinomas (P = .009). Hemizygous and homozygous deletions in 9p, where CDKN2 resides, were found in 92% (11 of 12) of uncultured squamous cell carcinomas, while only about 39% (35 of 90) of transitional cell carcinomas showed these losses (P = .001). Deletions in 9p with no change in 9q were found in 92% (10 of 11) of squamous cell carcinomas compared with only 10% (11 of 110) of transitional cell carcinomas (P<.001) reported in the literature. The frequency of p53 mutations in squamous cell carcinomas was similar to that reported for invasive transitional cell carcinomas (60%), but the type and position of mutations differed between the two tumor types. Allelic losses in chromosome arm 17p, where the p53 gene resides, were found to be less frequent in squamous cell carcinomas (38%) than in invasive transitional cell carcinomas (60%). Conclusions: Our results suggest that a putative tumor suppressor gene on 9p, possibly CDKN2, may contribute to squamous cell carcinoma tumorigenesis. Our data on squamous cell carcinoma and previously reported data on transitional cell carcinoma indicate that these two bladder carcinomas differ in their genetic alterations, suggesting that distinct underlying genetic defects may explain, at least in part, the pathological differences between the two tumors of the bladder epithelium. Implications: Development of diagnostic and therapeutic strategies for squamous cell carcinoma of the bladder based on its distinct genetic alterations is warranted. [J Natl Cancer Inst 1995;87:1383-93]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
A. Shibata, J. Parsonnet, T. A. Longacre, M. I. Garcia, B. Puligandla, R.E. Davis, J. H. Vogelman, N. Orentreich, and L. A. Habel
CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma
Carcinogenesis, March 1, 2002; 23(3): 419 - 424.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Muscheck, H. Abol-Enein, K. Chew, D. Moore II, V. Bhargava, M.A. Ghoneim, P.R. Carroll, and F.M. Waldman
Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization
Carcinogenesis, September 1, 2000; 21(9): 1721 - 1726.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Hartmann, K. Moser, M. Kriegmair, A. Hofstetter, F. Hofstaedter, and R. Knuechel
Frequent Genetic Alterations in Simple Urothelial Hyperplasias of the Bladder in Patients with Papillary Urothelial Carcinoma
Am. J. Pathol., March 1, 1999; 154(3): 721 - 727.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.